Dementia With Lewy Bodies clinical trials

Explore recruiting dementia with lewy bodies clinical trials.

Recruiting dementia with lewy bodies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dementia With Lewy Bodies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase IIa multicentre randomized controlled double blind clinical trial to demonstrate clinical efficacy on cognitive, neuropsychiatric and functional outcomes of Ambroxol in New and Early patients with prodromal and mild Dementia with Lewybodies (The ANeED study)

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)

Bulgaria, Czechia, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Czechia, Italy, France, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1 study to evaluate [18F]ACI-15916 as a potential PET radioligand for imaging α-synuclein deposits in the brain of patients with suspected α-synuclein pathology compared with healthy volunteers

Sweden

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Dementia With Lewy Bodies trials by city

Dementia With Lewy Bodies in Toronto Dementia With Lewy Bodies in Vancouver Dementia With Lewy Bodies in Montreal Dementia With Lewy Bodies in Calgary Dementia With Lewy Bodies in Edmonton Dementia With Lewy Bodies in Ottawa Dementia With Lewy Bodies in Winnipeg Dementia With Lewy Bodies in Quebec City Dementia With Lewy Bodies in Hamilton Dementia With Lewy Bodies in Kitchener Dementia With Lewy Bodies in London Dementia With Lewy Bodies in Halifax Dementia With Lewy Bodies in New York Dementia With Lewy Bodies in Los Angeles Dementia With Lewy Bodies in Chicago Dementia With Lewy Bodies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease